Get the Stockscreener App
7.74
1.71%
-0.135
After Hours:
7.64
-0.10
-1.29%
Corbus Pharmaceuticals Holdings Inc stock is traded at $7.74, with a volume of 787.26K.
It is down -1.71% in the last 24 hours and down -25.43% over the past month.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
See More
Previous Close:
$7.875
Open:
$7.83
24h Volume:
787.26K
Relative Volume:
1.15
Market Cap:
$149.70M
Revenue:
$1.54M
Net Income/Loss:
$-84.53M
P/E Ratio:
-1.3312
EPS:
-5.8145
Net Cash Flow:
$-73.65M
1W Performance:
+6.61%
1M Performance:
-25.43%
6M Performance:
-8.19%
1Y Performance:
-32.93%
1-Day Range:
$7.66
$7.98
1-Week Range:
$7.03
$7.98
52-Week Range:
$6.325
$20.56
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Name
Corbus Pharmaceuticals Holdings Inc
Sector
Industry
Phone
617-963-0103
Address
500 RIVER RIDGE DRIVE, NORWOOD, MA
Compare CRBP vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
7.74 | 152.31M | 1.54M | -84.53M | -73.65M | -5.8145 |
VRTX
Vertex Pharmaceuticals Inc
|
516.34 | 130.53B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
801.82 | 82.77B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
182.11 | 72.88B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
945.82 | 60.30B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
365.00 | 41.64B | 5.76B | 514.49M | 1.10B | 4.4813 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Resumed | B. Riley Securities | Buy |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Dec-02-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Initiated | Wedbush | Outperform |
| Jul-22-24 | Resumed | H.C. Wainwright | Buy |
| Jun-26-24 | Initiated | B. Riley Securities | Buy |
| Jun-03-24 | Reiterated | Oppenheimer | Outperform |
| May-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Mar-06-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-08-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-08-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-08-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-08-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Jul-07-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Mar-26-20 | Initiated | Nomura | Buy |
| Apr-05-19 | Initiated | Jefferies | Buy |
| Mar-20-19 | Initiated | Oppenheimer | Outperform |
| Jan-11-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-26-18 | Initiated | H.C. Wainwright | Buy |
| Dec-07-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-18 | Initiated | B. Riley FBR | Buy |
| Jan-19-18 | Initiated | Raymond James | Outperform |
| Dec-14-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-08-17 | Reiterated | Noble Financial | Buy |
| Sep-29-17 | Resumed | Noble Financial | Buy |
| Mar-30-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-15-16 | Reiterated | JMP Securities | Mkt Outperform |
| Nov-11-16 | Reiterated | Noble Financial | Buy |
View All
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Latest News
Corbus Pharmaceuticals stock holds at USD 1.56 - AD HOC NEWS
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
symbol__ Stock Quote Price and Forecast - CNN
CRBP - Finviz
Is CRBP a Good Cannabis Investment After Positive Obesity Study Data? - Yahoo Finance
H.C. Wainwright Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Corbus Pharmaceuticals Holdings Inc. Stock Rallies 4.9%, Outperforms Peers - webull.com
Corbus Pharmaceuticals Insider Ben Yong Offloads 2,000 Shares at $7.84 Each (NASDAQ: CRBP) - kalkinemedia.com
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
H.C. Wainwright reiterates Corbus stock rating on phase 1b data By Investing.com - Investing.com UK
Corbus CRB-913 Delivers 5% Weight Loss in Phase 1b Obesity Study - Yahoo Finance
Corbus reports phase 1b obesity drug trial results By Investing.com - Investing.com South Africa
CRBP: CRB-913 achieved 5% weight loss in 12 weeks with favorable safety, supporting further clinical development - TradingView
CRBP: CRB-913 achieved 5% weight loss in 12 weeks with mild side effects, supporting further development - TradingView
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $33 - Moomoo
Why is Corbus Pharmaceuticals stock surging today? By Investing.com - Investing.com Canada
Form 8K Corbus Pharmaceuticals Holding For: 14 September By Investing.com - Investing.com India
Corbus Pharmaceuticals stock rises on obesity drug trial data By Investing.com - Investing.com Australia
CRBP: CRB-701 and CRB-913 show promising efficacy and safety, advancing to pivotal studies - TradingView
Corbus Pharmaceuticals stock rises on obesity drug trial data - Investing.com
Corbus Pharmaceuticals Reports Positive Topline Data From CANYON-1 Study Of Daily Oral CRB-913 For Obesity Treatment - marketscreener.com
Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga
An obesity pill produced 5% weight loss in 12 weeks, with no plateau seen - Stock Titan
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity - Yahoo! Finance Canada
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
We Think Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Needs To Drive Business Growth Carefully - Moomoo
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings stock holds steady ahead of next results - AD HOC NEWS
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
How Corbus Pharmaceuticals Holdings Inc. (CRBP) Affects Rotational Strategy Timing - Stock Traders Daily
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals Holding (CRBP) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Corbus (CRBP) Outlook: Finishes 4.62% Higher at $10.86 for the Current Session - vinanet.vn
Corbus Pharmaceuticals Holdings, Inc. Revenue Breakdown – NASDAQ:CRBP - TradingView
CRBP’s CRB-701 Phase 3 Trial Sets the Stage for a Key Oncology Catalyst - The Globe and Mail
CRBP Q2 2026 Earnings: Wider-Than-Expected Loss of $1.81 Per Share, Yet Shares Advance 3.96%Earnings Yield Spread - vinanet.vn
Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Corbus Pharmaceuticals (CRBP) Holds Near $10.09 as Traders Eye $10.59 ResistanceOption Breadth - vinanet.vn
Corbus Pharmaceuticals (CRBP) Holds Near $10 as Buyers Defend Key SupportCovered Call ETF - vinanet.vn
Corbus Pharmaceuticals (CRBP): Citadel entities and Kenneth Griffin disclose 1.1% stake - Stock Titan
Price-Driven Insight from (CRBP) for Rule-Based Strategy - Stock Traders Daily
Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Corbus Pharmaceuticals (CRBP) - The Globe and Mail
Mizuho lowers Corbus Pharmaceuticals stock price target on model updates - Investing.com
Mizuho lowers Corbus Pharmaceuticals stock price target on model updates By Investing.com - Investing.com Canada
CRBP Insider Buying: Chief Business Officer Nishant Saxena Purch - GuruFocus
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Cuts Target Price to $33 - Moomoo
Corbus Pharmaceuticals (NASDAQ:CRBP) Insider Buys 2,600 Shares of Stock - MarketBeat
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):